var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FPL7ZCRAW%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FPL7ZCRAW%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FPL7ZCRAW%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
    2. \n
  2. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
    3. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2021\n \n \n (5)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD.\n \n \n \n \n\n\n \n Martin, A.; Hancox, R. J; Chang, C. L; Beasley, R.; Wrobel, J.; McDonald, V.; Dobler, C. C; Yang, I. A; Farah, C. S; Cochrane, B.; Hillis, G. S; Scowcroft, C. P.; Aggarwal, A.; Di Tanna, G. L.; Balicki, G.; Galgey, S.; and Jenkins, C.\n\n\n \n\n\n\n BMJ Open, 11(8): e053446. August 2021.\n \n\n\n\n
\n\n\n\n \n \n \"PreventingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 6 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{martin_preventing_2021,\n\ttitle = {Preventing adverse cardiac events ({PACE}) in chronic obstructive pulmonary disease ({COPD}): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in {COPD}},\n\tvolume = {11},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {Preventing adverse cardiac events ({PACE}) in chronic obstructive pulmonary disease ({COPD})},\n\turl = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2021-053446},\n\tdoi = {10.1136/bmjopen-2021-053446},\n\tabstract = {Introduction\n              Heart disease in chronic obstructive pulmonary disease (COPD) is a common but neglected comorbidity. Patients with COPD are frequently excluded from clinical trials of treatments aimed at reducing cardiac morbidity and mortality, which has led to undertreatment of cardiovascular disease in patients with COPD. A particular concern in COPD is the underuse of beta (β)-blockers. There is observational evidence that cardioselective β-blockers are safe and may even reduce mortality risk in COPD, although some evidence is conflicting. There is an urgent need to answer the research question: Are cardioselective β-blockers safe and of benefit in people with moderately severe COPD? The proposed study will investigate whether cardioselective β-blocker treatment in patients with COPD reduces mortality and cardiac and respiratory morbidity.\n            \n            \n              Methods and analyses\n              This is a double-blind, randomised controlled trial to be conducted in approximately 26 sites in Australia, New Zealand, India, Sri Lanka and other countries as required. Participants with COPD will be randomised to either bisoprolol once daily (range 1.25–5 mg, dependent on tolerated dose) or matched placebo, in addition to receiving usual care for their COPD over the study duration of 24 months.\n              \n                The study will enrol 1164 participants with moderate to severe COPD, aged 40–85 years. Participants will be symptomatic from their COPD and have a postbronchodilator forced expiratory volume in 1 s (FEV\n                1\n                ) ≥30\\% and ≤70\\% predicted and a history of at least one exacerbation requiring systemic corticosteroids, antibiotics or both in the prior 24 months.\n              \n            \n            \n              Ethics and dissemination\n              The study protocol has been approved by the Sydney Local Health District Human Research Ethics Committee at The Concord Repatriation General Hospital.\n            \n            \n              Trial registration numbers\n              \n                NCT03917914\n                ; CTRI/2020/08/027322.},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2021-10-02},\n\tjournal = {BMJ Open},\n\tauthor = {Martin, Allison and Hancox, Robert J and Chang, Catherina L and Beasley, Richard and Wrobel, Jeremy and McDonald, Vanessa and Dobler, Claudia C and Yang, Ian A and Farah, Claude S and Cochrane, Belinda and Hillis, Graham S and Scowcroft, Caroline Polak and Aggarwal, Ashutosh and Di Tanna, Gian Luca and Balicki, Grace and Galgey, Shane and Jenkins, Christine},\n\tmonth = aug,\n\tyear = {2021},\n\tpages = {e053446},\n}\n\n
\n
\n\n\n
\n Introduction Heart disease in chronic obstructive pulmonary disease (COPD) is a common but neglected comorbidity. Patients with COPD are frequently excluded from clinical trials of treatments aimed at reducing cardiac morbidity and mortality, which has led to undertreatment of cardiovascular disease in patients with COPD. A particular concern in COPD is the underuse of beta (β)-blockers. There is observational evidence that cardioselective β-blockers are safe and may even reduce mortality risk in COPD, although some evidence is conflicting. There is an urgent need to answer the research question: Are cardioselective β-blockers safe and of benefit in people with moderately severe COPD? The proposed study will investigate whether cardioselective β-blocker treatment in patients with COPD reduces mortality and cardiac and respiratory morbidity. Methods and analyses This is a double-blind, randomised controlled trial to be conducted in approximately 26 sites in Australia, New Zealand, India, Sri Lanka and other countries as required. Participants with COPD will be randomised to either bisoprolol once daily (range 1.25–5 mg, dependent on tolerated dose) or matched placebo, in addition to receiving usual care for their COPD over the study duration of 24 months. The study will enrol 1164 participants with moderate to severe COPD, aged 40–85 years. Participants will be symptomatic from their COPD and have a postbronchodilator forced expiratory volume in 1 s (FEV 1 ) ≥30% and ≤70% predicted and a history of at least one exacerbation requiring systemic corticosteroids, antibiotics or both in the prior 24 months. Ethics and dissemination The study protocol has been approved by the Sydney Local Health District Human Research Ethics Committee at The Concord Repatriation General Hospital. Trial registration numbers NCT03917914 ; CTRI/2020/08/027322.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n New Zealand COPD Guidelines: Quick Reference Guide.\n \n \n \n\n\n \n Hancox, R. J.; Jones, S.; Baggott, C.; Chen, D.; Corna, N.; Davies, C.; Fingleton, J.; Hardy, J.; Hussain, S.; Poot, B.; Reid, J.; Travers, J.; Turner, J.; and Young, R.\n\n\n \n\n\n\n The New Zealand Medical Journal, 134(1530): 76–110. February 2021.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{hancox_new_2021,\n\ttitle = {New {Zealand} {COPD} {Guidelines}: {Quick} {Reference} {Guide}},\n\tvolume = {134},\n\tissn = {1175-8716},\n\tshorttitle = {New {Zealand} {COPD} {Guidelines}},\n\tabstract = {The purpose of the Asthma and Respiratory Foundation of New Zealand's COPD Guidelines: Quick Reference Guide is to provide simple, practical, evidence-based recommendations for the diagnosis, assessment, and management of chronic obstructive pulmonary disease (COPD) in clinical practice. The intended users are health professionals responsible for delivering acute and chronic COPD care in community and hospital settings, and those responsible for the training of such health professionals.},\n\tlanguage = {eng},\n\tnumber = {1530},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Hancox, Robert J. and Jones, Stuart and Baggott, Christina and Chen, David and Corna, Nicola and Davies, Cheryl and Fingleton, James and Hardy, Jo and Hussain, Syed and Poot, Betty and Reid, Jim and Travers, Justin and Turner, Joanna and Young, Robert},\n\tmonth = feb,\n\tyear = {2021},\n\tpmid = {33651780},\n\tkeywords = {Delivery of Health Care, Foundations, Health Knowledge, Attitudes, Practice, Health Personnel, Humans, New Zealand, Pulmonary Disease, Chronic Obstructive},\n\tpages = {76--110},\n}\n\n
\n
\n\n\n
\n The purpose of the Asthma and Respiratory Foundation of New Zealand's COPD Guidelines: Quick Reference Guide is to provide simple, practical, evidence-based recommendations for the diagnosis, assessment, and management of chronic obstructive pulmonary disease (COPD) in clinical practice. The intended users are health professionals responsible for delivering acute and chronic COPD care in community and hospital settings, and those responsible for the training of such health professionals.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD.\n \n \n \n \n\n\n \n Karlsson, N.; Atkinson, M. J.; Müllerová, H.; Alacqua, M.; Keen, C.; Hughes, R.; Janson, C.; Make, B.; Price, D.; and Reddel, H. K.\n\n\n \n\n\n\n ERJ Open Research, 7(1): 00828–2020. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ValidationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{karlsson_validation_2021,\n\ttitle = {Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or {COPD}},\n\tvolume = {7},\n\tissn = {2312-0541},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00828-2020},\n\tdoi = {10.1183/23120541.00828-2020},\n\tabstract = {Background\n              The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD).\n            \n            \n              Methods\n              \n                Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study (\n                ClinicalTrials.gov\n                :\n                NCT02760329\n                ). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses.\n              \n            \n            \n              Results\n              \n                For the total sample, the mean±\n                sd\n                RSQ score was 5.6±4.3 (range 0–16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76–0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of –2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7–2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p{\\textless}0.001).\n              \n            \n            \n              Conclusions\n              The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-30},\n\tjournal = {ERJ Open Research},\n\tauthor = {Karlsson, Niklas and Atkinson, Mark J. and Müllerová, Hana and Alacqua, Marianna and Keen, Christina and Hughes, Rod and Janson, Christer and Make, Barry and Price, David and Reddel, Helen K.},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {00828--2020},\n}\n\n
\n
\n\n\n
\n Background The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD). Methods Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study ( ClinicalTrials.gov : NCT02760329 ). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses. Results For the total sample, the mean± sd RSQ score was 5.6±4.3 (range 0–16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76–0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of –2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7–2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p\\textless0.001). Conclusions The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.\n \n \n \n \n\n\n \n Reddel, H. K; Vestbo, J.; Agustí, A.; Anderson, G. P; Bansal, A. T; Beasley, R.; Bel, E. H; Janson, C.; Make, B.; Pavord, I. D; Price, D.; Rapsomaniki, E.; Karlsson, N.; Finch, D. K; Nuevo, J.; de Giorgio-Miller, A.; Alacqua, M.; Hughes, R.; Müllerová, H.; and Gerhardsson de Verdier, M.\n\n\n \n\n\n\n European Respiratory Journal,2003927. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"HeterogeneityPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{reddel_heterogeneity_2021,\n\ttitle = {Heterogeneity within and between physician-diagnosed asthma and/or {COPD}: {NOVELTY} cohort},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Heterogeneity within and between physician-diagnosed asthma and/or {COPD}},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03927-2020},\n\tdoi = {10.1183/13993003.03927-2020},\n\tabstract = {Background\n              Studies of asthma and chronic obstructive pulmonary disease (COPD) typically focus on these diagnoses separately, limiting understanding of disease mechanisms and treatment options. NOVELTY is a global, 3-year, prospective observational study of patients with asthma and/or COPD from real-world clinical practice. We investigated heterogeneity and overlap by diagnosis and severity in this cohort.\n            \n            \n              Methods\n              Patients with physician-assigned asthma, COPD or both (asthma+COPD) were enrolled, stratified by diagnosis and severity. Baseline characteristics were reported descriptively by physician-assigned diagnosis and/or severity. Factors associated with physician-assessed severity were evaluated using ordinal logistic regression analysis.\n            \n            \n              Results\n              \n                Of 11 243 patients, 5940 (52.8\\%) had physician-assigned asthma, 1396 (12.4\\%) had asthma+COPD and 3907 (34.8\\%) had COPD; almost half were from primary care. Symptoms, health-related quality of life and spirometry showed substantial heterogeneity and overlap between asthma, asthma+COPD and COPD, with 23\\%, 62\\% and 64\\% of patients, respectively, having post-bronchodilator FEV\n                1\n                /FVC {\\textless}lower limit of normal.\n              \n              Symptoms and exacerbations increased with greater physician-assessed severity, and were higher in asthma+COPD, but 24.3\\% with mild asthma and 20.4\\% with mild COPD had experienced ≥1 exacerbation in the past 12 months. Medication records suggested both under-treatment and over-treatment relative to severity. Blood eosinophil counts varied little across diagnosis/severity groups, but blood neutrophil counts increased with severity across all diagnoses.\n            \n            \n              Conclusion\n              This analysis demonstrates marked heterogeneity within, and overlap between, physician-assigned diagnosis and severity groups in patients with asthma and/or COPD. Current diagnostic and severity classifications in clinical practice poorly differentiate between clinical phenotypes that may have specific risks and treatment implications.},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Reddel, Helen K and Vestbo, Jørgen and Agustí, Alvar and Anderson, Gary P and Bansal, Aruna T and Beasley, Richard and Bel, Elisabeth H and Janson, Christer and Make, Barry and Pavord, Ian D and Price, David and Rapsomaniki, Eleni and Karlsson, Niklas and Finch, Donna K and Nuevo, Javier and de Giorgio-Miller, Alex and Alacqua, Marianna and Hughes, Rod and Müllerová, Hana and Gerhardsson de Verdier, Maria},\n\tmonth = feb,\n\tyear = {2021},\n\tpages = {2003927},\n}\n\n
\n
\n\n\n
\n Background Studies of asthma and chronic obstructive pulmonary disease (COPD) typically focus on these diagnoses separately, limiting understanding of disease mechanisms and treatment options. NOVELTY is a global, 3-year, prospective observational study of patients with asthma and/or COPD from real-world clinical practice. We investigated heterogeneity and overlap by diagnosis and severity in this cohort. Methods Patients with physician-assigned asthma, COPD or both (asthma+COPD) were enrolled, stratified by diagnosis and severity. Baseline characteristics were reported descriptively by physician-assigned diagnosis and/or severity. Factors associated with physician-assessed severity were evaluated using ordinal logistic regression analysis. Results Of 11 243 patients, 5940 (52.8%) had physician-assigned asthma, 1396 (12.4%) had asthma+COPD and 3907 (34.8%) had COPD; almost half were from primary care. Symptoms, health-related quality of life and spirometry showed substantial heterogeneity and overlap between asthma, asthma+COPD and COPD, with 23%, 62% and 64% of patients, respectively, having post-bronchodilator FEV 1 /FVC \\textlesslower limit of normal. Symptoms and exacerbations increased with greater physician-assessed severity, and were higher in asthma+COPD, but 24.3% with mild asthma and 20.4% with mild COPD had experienced ≥1 exacerbation in the past 12 months. Medication records suggested both under-treatment and over-treatment relative to severity. Blood eosinophil counts varied little across diagnosis/severity groups, but blood neutrophil counts increased with severity across all diagnoses. Conclusion This analysis demonstrates marked heterogeneity within, and overlap between, physician-assigned diagnosis and severity groups in patients with asthma and/or COPD. Current diagnostic and severity classifications in clinical practice poorly differentiate between clinical phenotypes that may have specific risks and treatment implications.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Searching for the optimal oxygen saturation range in acutely unwell patients.\n \n \n \n \n\n\n \n Pilcher, J. M.; Kearns, C.; and Beasley, R.\n\n\n \n\n\n\n Emergency Medicine Journal, 38(3): 168–169. March 2021.\n \n\n\n\n
\n\n\n\n \n \n \"SearchingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 5 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pilcher_searching_2021,\n\ttitle = {Searching for the optimal oxygen saturation range in acutely unwell patients},\n\tvolume = {38},\n\tissn = {1472-0205, 1472-0213},\n\turl = {https://emj.bmj.com/lookup/doi/10.1136/emermed-2020-210749},\n\tdoi = {10.1136/emermed-2020-210749},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2021-02-24},\n\tjournal = {Emergency Medicine Journal},\n\tauthor = {Pilcher, Janine Marie and Kearns, Ciléin and Beasley, Richard},\n\tmonth = mar,\n\tyear = {2021},\n\tpages = {168--169},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2020\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Characteristics and Outcomes of Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Australia and New Zealand.\n \n \n \n \n\n\n \n Berenyi, F.; Steinfort, D. P.; Abdelhamid, Y. A.; Bailey, M. J.; Pilcher, D. V.; Bellomo, R.; Finnis, M. E.; Young, P. J.; and Deane, A. M.\n\n\n \n\n\n\n Annals of the American Thoracic Society, 17(6): 736–745. June 2020.\n \n\n\n\n
\n\n\n\n \n \n \"CharacteristicsPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{berenyi_characteristics_2020,\n\ttitle = {Characteristics and {Outcomes} of {Critically} {Ill} {Patients} with {Acute} {Exacerbation} of {Chronic} {Obstructive} {Pulmonary} {Disease} in {Australia} and {New} {Zealand}},\n\tvolume = {17},\n\tissn = {2329-6933, 2325-6621},\n\turl = {https://www.atsjournals.org/doi/10.1513/AnnalsATS.201911-821OC},\n\tdoi = {10.1513/AnnalsATS.201911-821OC},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2021-05-07},\n\tjournal = {Annals of the American Thoracic Society},\n\tauthor = {Berenyi, Freya and Steinfort, Daniel P. and Abdelhamid, Yasmine Ali and Bailey, Michael J. and Pilcher, David V. and Bellomo, Rinaldo and Finnis, Mark E. and Young, Paul J. and Deane, Adam M.},\n\tmonth = jun,\n\tyear = {2020},\n\tpages = {736--745},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Closed-Loop Oxygen Control Using a Novel Nasal High-Flow Device: A Randomized Crossover Trial.\n \n \n \n \n\n\n \n Harper, J. C.; Kearns, N. A; Maijers, I.; Bird, G. E; Braithwaite, I.; Shortt, N. P; Eathorne, A.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respiratory Care,respcare.08087. October 2020.\n \n\n\n\n
\n\n\n\n \n \n \"Closed-LoopPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{harper_closed-loop_2020,\n\ttitle = {Closed-{Loop} {Oxygen} {Control} {Using} a {Novel} {Nasal} {High}-{Flow} {Device}: {A} {Randomized} {Crossover} {Trial}},\n\tissn = {0020-1324, 1943-3654},\n\tshorttitle = {Closed-{Loop} {Oxygen} {Control} {Using} a {Novel} {Nasal} {High}-{Flow} {Device}},\n\turl = {http://rc.rcjournal.com/lookup/doi/10.4187/respcare.08087},\n\tdoi = {10.4187/respcare.08087},\n\tlanguage = {en},\n\turldate = {2020-12-02},\n\tjournal = {Respiratory Care},\n\tauthor = {Harper, James CP and Kearns, Nethmi A and Maijers, Ingrid and Bird, Grace E and Braithwaite, Irene and Shortt, Nicholas P and Eathorne, Allie and Weatherall, Mark and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2020},\n\tpages = {respcare.08087},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Searching for the optimal oxygen saturation range in acutely unwell patients.\n \n \n \n \n\n\n \n Pilcher, J. M.; Kearns, C.; and Beasley, R.\n\n\n \n\n\n\n Emergency Medicine Journal,emermed–2020–210749. November 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SearchingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pilcher_searching_2020,\n\ttitle = {Searching for the optimal oxygen saturation range in acutely unwell patients},\n\tissn = {1472-0205, 1472-0213},\n\turl = {https://emj.bmj.com/lookup/doi/10.1136/emermed-2020-210749},\n\tdoi = {10.1136/emermed-2020-210749},\n\tlanguage = {en},\n\turldate = {2020-11-27},\n\tjournal = {Emergency Medicine Journal},\n\tauthor = {Pilcher, Janine Marie and Kearns, Ciléin and Beasley, Richard},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {emermed--2020--210749},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Taking Charge: A Proposed Psychological Intervention to Improve Pulmonary Rehabilitation Outcomes for People with COPD.\n \n \n \n \n\n\n \n McNaughton, A.; Levack, W.; and McNaughton, H.\n\n\n \n\n\n\n International Journal of Chronic Obstructive Pulmonary Disease, Volume 15: 2127–2133. September 2020.\n \n\n\n\n
\n\n\n\n \n \n \"TakingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mcnaughton_taking_2020,\n\ttitle = {Taking {Charge}: {A} {Proposed} {Psychological} {Intervention} to {Improve} {Pulmonary} {Rehabilitation} {Outcomes} for {People} with {COPD}},\n\tvolume = {Volume 15},\n\tissn = {1178-2005},\n\tshorttitle = {Taking {Charge}},\n\turl = {https://www.dovepress.com/taking-charge-a-proposed-psychological-intervention-to-improve-pulmona-peer-reviewed-article-COPD},\n\tdoi = {10.2147/COPD.S267268},\n\tlanguage = {en},\n\turldate = {2020-09-14},\n\tjournal = {International Journal of Chronic Obstructive Pulmonary Disease},\n\tauthor = {McNaughton, Amanda and Levack, William and McNaughton, Harry},\n\tmonth = sep,\n\tyear = {2020},\n\tpages = {2127--2133},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2019\n \n \n (7)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Prospective observational study in patients with obstructive lung disease: NOVELTY design.\n \n \n \n \n\n\n \n Reddel, H. K.; Gerhardsson de Verdier, M.; Agustí, A.; Anderson, G.; Beasley, R.; Bel, E. H.; Janson, C.; Make, B.; Martin, R. J.; Pavord, I.; Price, D.; Keen, C.; Gardev, A.; Rennard, S.; Sveréus, A.; Bansal, A. T.; Brannman, L.; Karlsson, N.; Nuevo, J.; Nyberg, F.; Young, S. S.; and Vestbo, J.\n\n\n \n\n\n\n ERJ Open Research, 5(1): 00036–2018. February 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"ProspectivePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{reddel_prospective_2019,\n\ttitle = {Prospective observational study in patients with obstructive lung disease: {NOVELTY} design},\n\tvolume = {5},\n\tissn = {2312-0541},\n\tshorttitle = {Prospective observational study in patients with obstructive lung disease},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00036-2018},\n\tdoi = {10.1183/23120541.00036-2018},\n\tabstract = {Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma–COPD overlap are limited. NOVELTY is a global, prospective observational 3-year study enrolling ∼12 000 patients ≥12 years of age from primary and specialist clinical practices in 19 countries (ClinicalTrials.gov identifier:\n              NCT02760329\n              ).\n            \n            NOVELTY's primary objectives are to describe patient characteristics, treatment patterns and disease burden over time, and to identify phenotypes and molecular endotypes associated with differential outcomes over time in patients with a diagnosis/suspected diagnosis of asthma and/or COPD. NOVELTY aims to recruit real-world patients, unlike clinical studies with restrictive inclusion/exclusion criteria.\n            \n              Data collected at yearly intervals include clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs) and healthcare utilisation (HCU). PROs and HCU will also be collected 3-monthly\n              via\n              internet/telephone. Data will be used to identify phenotypes and endotypes associated with different trajectories for symptom burden, clinical progression or remission and HCU. Results may allow patient classification across obstructive lung disease by clinical outcomes and biomarker profile, rather than by conventional diagnostic labels and severity categories.\n            \n            NOVELTY will provide a rich data source on obstructive lung disease, to help improve patient outcomes and aid novel drug development.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {ERJ Open Research},\n\tauthor = {Reddel, Helen K. and Gerhardsson de Verdier, Maria and Agustí, Alvar and Anderson, Gary and Beasley, Richard and Bel, Elisabeth H. and Janson, Christer and Make, Barry and Martin, Richard J. and Pavord, Ian and Price, David and Keen, Christina and Gardev, Asparuh and Rennard, Stephen and Sveréus, Alecka and Bansal, Aruna T. and Brannman, Lance and Karlsson, Niklas and Nuevo, Javier and Nyberg, Fredrik and Young, Simon S. and Vestbo, Jørgen},\n\tmonth = feb,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {00036--2018},\n}\n\n
\n
\n\n\n
\n Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma–COPD overlap are limited. NOVELTY is a global, prospective observational 3-year study enrolling ∼12 000 patients ≥12 years of age from primary and specialist clinical practices in 19 countries (ClinicalTrials.gov identifier: NCT02760329 ). NOVELTY's primary objectives are to describe patient characteristics, treatment patterns and disease burden over time, and to identify phenotypes and molecular endotypes associated with differential outcomes over time in patients with a diagnosis/suspected diagnosis of asthma and/or COPD. NOVELTY aims to recruit real-world patients, unlike clinical studies with restrictive inclusion/exclusion criteria. Data collected at yearly intervals include clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs) and healthcare utilisation (HCU). PROs and HCU will also be collected 3-monthly via internet/telephone. Data will be used to identify phenotypes and endotypes associated with different trajectories for symptom burden, clinical progression or remission and HCU. Results may allow patient classification across obstructive lung disease by clinical outcomes and biomarker profile, rather than by conventional diagnostic labels and severity categories. NOVELTY will provide a rich data source on obstructive lung disease, to help improve patient outcomes and aid novel drug development.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial.\n \n \n \n \n\n\n \n McKinstry, S.; Singer, J.; Baarsma, J. P.; Weatherall, M.; Beasley, R.; and Fingleton, J.\n\n\n \n\n\n\n Respirology, 24(11): 1081–1087. November 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n \n \"NasalPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mckinstry_nasal_2019,\n\ttitle = {Nasal high‐flow therapy compared with non‐invasive ventilation in {COPD} patients with chronic respiratory failure: {A} randomized controlled cross‐over trial},\n\tvolume = {24},\n\tissn = {1323-7799, 1440-1843},\n\tshorttitle = {Nasal high‐flow therapy compared with non‐invasive ventilation in {COPD} patients with chronic respiratory failure},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13575},\n\tdoi = {10.1111/resp.13575},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2020-08-23},\n\tjournal = {Respirology},\n\tauthor = {McKinstry, Steven and Singer, Joseph and Baarsma, Jan Pieter and Weatherall, Mark and Beasley, Richard and Fingleton, James},\n\tmonth = nov,\n\tyear = {2019},\n\tnote = {Number: 11},\n\tpages = {1081--1087},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Accuracy and precision of transcutaneous carbon dioxide monitoring: a systematic review and meta-analysis.\n \n \n \n \n\n\n \n Conway, A.; Tipton, E.; Liu, W.; Conway, Z.; Soalheira, K.; Sutherland, J.; and Fingleton, J.\n\n\n \n\n\n\n Thorax, 74(2): 157–163. February 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n \"AccuracyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{conway_accuracy_2019,\n\ttitle = {Accuracy and precision of transcutaneous carbon dioxide monitoring: a systematic review and meta-analysis},\n\tvolume = {74},\n\tissn = {0040-6376, 1468-3296},\n\tshorttitle = {Accuracy and precision of transcutaneous carbon dioxide monitoring},\n\turl = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2017-211466},\n\tdoi = {10.1136/thoraxjnl-2017-211466},\n\tabstract = {Background\n              \n                Transcutaneous carbon dioxide (TcCO\n                2\n                ) monitoring is a non-invasive alternative to arterial blood sampling. The aim of this review was to determine the accuracy and precision of TcCO\n                2\n                measurements.\n              \n            \n            \n              Methods\n              \n                Medline and EMBASE (2000–2016) were searched for studies that reported on a measurement of PaCO\n                2\n                that coincided with a measurement of TcCO\n                2\n                . Study selection and quality assessment (using the revised Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2)) were performed independently. The Grading Quality of Evidence and Strength of Recommendation approach was used to summarise the strength of the body of evidence. Pooled estimates of the mean bias between TcCO\n                2\n                and PaCO\n                2\n                and limits of agreement with outer 95\\% CIs (termed population limits of agreement) were calculated.\n              \n            \n            \n              Results\n              \n                The mean bias was −0.1 mm Hg and the population limits of agreement were −15 to 15 mm Hg for 7021 paired measurements taken from 2817 participants in 73 studies, which was outside of the clinically acceptable range (7.5 mm Hg). The lowest PaCO\n                2\n                reported in the studies was 18 mm Hg and the highest was 103 mm Hg. The major sources of inconsistency were sensor location and temperature. The population limits of agreement were within the clinically acceptable range across 3974 paired measurements from 1786 participants in 44 studies that applied the sensor to the earlobe using the TOSCA and Sentec devices (−6 to 6 mm Hg).\n              \n            \n            \n              Conclusion\n              \n                There are substantial differences between TcCO\n                2\n                and PaCO\n                2\n                depending on the context in which this technology is used. TcCO\n                2\n                sensors should preferentially be applied to the earlobe and users should consider setting the temperature of the sensor higher than 42°C when monitoring at other sites.\n              \n            \n            \n              Systematic review registration number\n              PROSPERO; CRD42017057450.},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {Thorax},\n\tauthor = {Conway, Aaron and Tipton, Elizabeth and Liu, Wei-Hong and Conway, Zachary and Soalheira, Kathleen and Sutherland, Joanna and Fingleton, James},\n\tmonth = feb,\n\tyear = {2019},\n\tnote = {Number: 2},\n\tpages = {157--163},\n}\n\n
\n
\n\n\n
\n Background Transcutaneous carbon dioxide (TcCO 2 ) monitoring is a non-invasive alternative to arterial blood sampling. The aim of this review was to determine the accuracy and precision of TcCO 2 measurements. Methods Medline and EMBASE (2000–2016) were searched for studies that reported on a measurement of PaCO 2 that coincided with a measurement of TcCO 2 . Study selection and quality assessment (using the revised Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2)) were performed independently. The Grading Quality of Evidence and Strength of Recommendation approach was used to summarise the strength of the body of evidence. Pooled estimates of the mean bias between TcCO 2 and PaCO 2 and limits of agreement with outer 95% CIs (termed population limits of agreement) were calculated. Results The mean bias was −0.1 mm Hg and the population limits of agreement were −15 to 15 mm Hg for 7021 paired measurements taken from 2817 participants in 73 studies, which was outside of the clinically acceptable range (7.5 mm Hg). The lowest PaCO 2 reported in the studies was 18 mm Hg and the highest was 103 mm Hg. The major sources of inconsistency were sensor location and temperature. The population limits of agreement were within the clinically acceptable range across 3974 paired measurements from 1786 participants in 44 studies that applied the sensor to the earlobe using the TOSCA and Sentec devices (−6 to 6 mm Hg). Conclusion There are substantial differences between TcCO 2 and PaCO 2 depending on the context in which this technology is used. TcCO 2 sensors should preferentially be applied to the earlobe and users should consider setting the temperature of the sensor higher than 42°C when monitoring at other sites. Systematic review registration number PROSPERO; CRD42017057450.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Sequence analysis of capnography waveform abnormalities during nurse-administered procedural sedation and analgesia in the cardiac catheterization laboratory.\n \n \n \n \n\n\n \n Conway, A.; Collins, P.; Chang, K.; Mafeld, S.; Sutherland, J.; and Fingleton, J.\n\n\n \n\n\n\n Scientific Reports, 9(1): 10214. December 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"SequencePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{conway_sequence_2019,\n\ttitle = {Sequence analysis of capnography waveform abnormalities during nurse-administered procedural sedation and analgesia in the cardiac catheterization laboratory},\n\tvolume = {9},\n\tissn = {2045-2322},\n\turl = {http://www.nature.com/articles/s41598-019-46751-2},\n\tdoi = {10.1038/s41598-019-46751-2},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {Scientific Reports},\n\tauthor = {Conway, Aaron and Collins, Peter and Chang, Kristina and Mafeld, Sebastian and Sutherland, Joanna and Fingleton, James},\n\tmonth = dec,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {10214},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia.\n \n \n \n \n\n\n \n Conway, A.; Collins, P.; Chang, K.; Mafeld, S.; Sutherland, J.; Fingleton, J.; and Parotto, M.\n\n\n \n\n\n\n Journal of Clinical Monitoring and Computing. September 2019.\n \n\n\n\n
\n\n\n\n \n \n \"Pre-apneicPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{conway_pre-apneic_2019,\n\ttitle = {Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia},\n\tissn = {1387-1307, 1573-2614},\n\turl = {http://link.springer.com/10.1007/s10877-019-00391-z},\n\tdoi = {10.1007/s10877-019-00391-z},\n\tlanguage = {en},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Clinical Monitoring and Computing},\n\tauthor = {Conway, Aaron and Collins, Peter and Chang, Kristina and Mafeld, Sebastian and Sutherland, Joanna and Fingleton, James and Parotto, Matteo},\n\tmonth = sep,\n\tyear = {2019},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial.\n \n \n \n\n\n \n McKinstry, S.; Singer, J.; Pieter Baarsma, J.; Weatherall, M.; Beasley, R.; and Fingleton, J.\n\n\n \n\n\n\n Respirology. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mckinstry_nasal_2019-1,\n\ttitle = {Nasal high‐flow therapy compared with non‐invasive ventilation in {COPD} patients with chronic respiratory failure: {A} randomized controlled cross‐over trial},\n\tdoi = {10.1111/resp.13575},\n\tjournal = {Respirology},\n\tauthor = {McKinstry, Steven and Singer, Joseph and Pieter Baarsma, Jan and Weatherall, Mark and Beasley, Richard and Fingleton, James},\n\tyear = {2019},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Pragmatic Randomized Controlled Trial of Budesonide/Formoterol Reliever Therapy in Adults with Mild Asthma.\n \n \n \n\n\n \n Beasley, R W; Holliday, M; Reddel, H K; Braithwaite, I; Ebmeier, S; Hancox, R; Harrison, T; Houghton, C; Oldfield, K; and Papi, A\n\n\n \n\n\n\n In D101. CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD, pages A7477–A7477. American Thoracic Society, 2019.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@incollection{beasley_pragmatic_2019,\n\ttitle = {Pragmatic {Randomized} {Controlled} {Trial} of {Budesonide}/{Formoterol} {Reliever} {Therapy} in {Adults} with {Mild} {Asthma}},\n\tisbn = {1073-449X},\n\tbooktitle = {D101. {CLINICAL} {AND} {TRANSLATIONAL} {STUDIES} {IN} {ASTHMA} {AND} {COPD}},\n\tpublisher = {American Thoracic Society},\n\tauthor = {Beasley, R W and Holliday, M and Reddel, H K and Braithwaite, I and Ebmeier, S and Hancox, R and Harrison, T and Houghton, C and Oldfield, K and Papi, A},\n\tyear = {2019},\n\tpages = {A7477--A7477},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2017\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n β-blockers in exacerbations of COPD: Feasibility of a randomised controlled trial.\n \n \n \n\n\n \n Chang, C.; Wong, C.; Beckert, L.; Shafuddin, E.; Beasley, R.; Young, R.; and J. Hancox, R.\n\n\n \n\n\n\n ERJ Open Research, 3: 90–2016. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{chang_-blockers_2017,\n\ttitle = {β-blockers in exacerbations of {COPD}: {Feasibility} of a randomised controlled trial},\n\tvolume = {3},\n\tdoi = {10.1183/23120541.00090-2016},\n\tjournal = {ERJ Open Research},\n\tauthor = {Chang, Catherina and Wong, Conroy and Beckert, Lutz and Shafuddin, Eskandarain and Beasley, Richard and Young, Robert and J. Hancox, Robert},\n\tyear = {2017},\n\tpages = {90--2016},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Physiological effects of titrated oxygen via nasal high-flow cannulae in COPD exacerbations: A randomized controlled cross-over trial.\n \n \n \n\n\n \n Pilcher, J.; Eastlake, L.; Richards, M.; Power, S.; Cripps, T.; Bibby, S.; Braithwaite, I.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respirology (Carlton, Vic.), 22. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pilcher_physiological_2017,\n\ttitle = {Physiological effects of titrated oxygen via nasal high-flow cannulae in {COPD} exacerbations: {A} randomized controlled cross-over trial},\n\tvolume = {22},\n\tdoi = {10.1111/resp.13050},\n\tjournal = {Respirology (Carlton, Vic.)},\n\tauthor = {Pilcher, Janine and Eastlake, Leonie and Richards, Michael and Power, Sharon and Cripps, Terrianne and Bibby, Susan and Braithwaite, Irene and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Oxygen compared to air driven nebulisers for acute exacerbations of COPD: a randomised controlled trial.\n \n \n \n\n\n \n Bardsley, G.; McKinstry, S.; Pilcher, J.; Fingleton, J.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n In pages PA684, 2017. \n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{bardsley_oxygen_2017,\n\ttitle = {Oxygen compared to air driven nebulisers for acute exacerbations of {COPD}: a randomised controlled trial},\n\tdoi = {10.1183/1393003.congress-2017.PA684},\n\tauthor = {Bardsley, George and McKinstry, Steve and Pilcher, Janine and Fingleton, James and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n\tpages = {PA684},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Nasal high flow therapy and PtCO2 in stable COPD: A randomized controlled cross‐over trial.\n \n \n \n\n\n \n McKinstry, S.; Pilcher, J.; Bardsley, G.; Berry, J.; de Hei, S.; Braithwaite, I.; Fingleton, J.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 23. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mckinstry_nasal_2017,\n\ttitle = {Nasal high flow therapy and {PtCO2} in stable {COPD}: {A} randomized controlled cross‐over trial},\n\tvolume = {23},\n\tdoi = {10.1111/resp.13185},\n\tjournal = {Respirology},\n\tauthor = {McKinstry, Steven and Pilcher, Janine and Bardsley, George and Berry, James and de Hei, Susanne and Braithwaite, Irene and Fingleton, James and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2016\n \n \n (3)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Target oxygen saturation range: 92-96% Versus 94-98%.\n \n \n \n\n\n \n Chien, J.; King, G.; Farah, C.; Walters, H.; Moore, R.; Douglas, J.; Smith, S.; Pilcher, J.; Eastlake, L.; Beasley, R.; and Richards, M.\n\n\n \n\n\n\n Respirology, 22(1): 200–202. 2016.\n Number: 1\n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{chien_target_2016,\n\ttitle = {Target oxygen saturation range: 92-96\\% {Versus} 94-98\\%},\n\tvolume = {22},\n\tdoi = {10.1111/resp.12879},\n\tnumber = {1},\n\tjournal = {Respirology},\n\tauthor = {Chien, Jimmy and King, Gregory and Farah, Claude and Walters, Haydn and Moore, Rosemary and Douglas, James and Smith, Sheree and Pilcher, Janine and Eastlake, Leonie and Beasley, Richard and Richards, Michael},\n\tyear = {2016},\n\tnote = {Number: 1},\n\tkeywords = {abbreviations, adult, apy, british thoracic society, bts, chronic, copd, fio 2, fraction of inspired, guideline, obstructive pulmonary disease, oxygen, oxygen inhalation ther-, target oxygen saturation range},\n\tpages = {200--202},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Sing Your Lungs Out: a qualitative study of a community singing group for people with chronic obstructive pulmonary disease (COPD).\n \n \n \n\n\n \n McNaughton, A.; Aldington, S.; Williams, G.; and Levack, W. M M\n\n\n \n\n\n\n BMJ open, 6(9): e012521. 2016.\n Number: 9 Publisher: British Medical Journal Publishing Group\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mcnaughton_sing_2016,\n\ttitle = {Sing {Your} {Lungs} {Out}: a qualitative study of a community singing group for people with chronic obstructive pulmonary disease ({COPD})},\n\tvolume = {6},\n\tissn = {2044-6055},\n\tnumber = {9},\n\tjournal = {BMJ open},\n\tauthor = {McNaughton, Amanda and Aldington, Sarah and Williams, Gayle and Levack, William M M},\n\tyear = {2016},\n\tnote = {Number: 9\nPublisher: British Medical Journal Publishing Group},\n\tpages = {e012521},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Reference ranges for serum periostin in a population without asthma or copd.\n \n \n \n\n\n \n Caswell-Smith, R.; Hosking, A.; Cripps, T.; Holweg, C.; Matthews, J; Holliday, M.; Maillot, C.; Fingleton, J.; Weatherall, M.; Braithwaite, I.; and Beasley, R.\n\n\n \n\n\n\n Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 46. 2016.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{caswell-smith_reference_2016,\n\ttitle = {Reference ranges for serum periostin in a population without asthma or copd},\n\tvolume = {46},\n\tdoi = {10.1111/cea.12763},\n\tjournal = {Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},\n\tauthor = {Caswell-Smith, Rachel and Hosking, Alexander and Cripps, Terrianne and Holweg, Cécile and Matthews, J and Holliday, Mark and Maillot, Corentin and Fingleton, James and Weatherall, Mark and Braithwaite, Irene and Beasley, Richard},\n\tyear = {2016},\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2014\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Little agreement in GOLD category using CAT and mMRC in 450 primary care COPD patients in New Zealand.\n \n \n \n\n\n \n Holt, S.; Sheahan, D.; Helm, C.; Tofield, C.; Corin, A.; and Kocks, J. W H\n\n\n \n\n\n\n NPJ primary care respiratory medicine, 24: 14025. 2014.\n Publisher: Nature Publishing Group\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{holt_little_2014,\n\ttitle = {Little agreement in {GOLD} category using {CAT} and {mMRC} in 450 primary care {COPD} patients in {New} {Zealand}},\n\tvolume = {24},\n\tissn = {2055-1010},\n\tjournal = {NPJ primary care respiratory medicine},\n\tauthor = {Holt, Shaun and Sheahan, Davitt and Helm, Colin and Tofield, Chris and Corin, Andrew and Kocks, Janwillem W H},\n\tyear = {2014},\n\tnote = {Publisher: Nature Publishing Group},\n\tpages = {14025},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2013\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: A randomised double-blind placebo-controlled trial.\n \n \n \n\n\n \n Edwards, L.; Shirtcliffe, P.; Wadsworth, K.; Healy, B.; Jefferies, S.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Thorax, 68. 2013.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 3 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{edwards_use_2013,\n\ttitle = {Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of {COPD} in adults: {A} randomised double-blind placebo-controlled trial},\n\tvolume = {68},\n\tdoi = {10.1136/thoraxjnl-2012-202225},\n\tjournal = {Thorax},\n\tauthor = {Edwards, Llifon and Shirtcliffe, Philippa and Wadsworth, Kirsten and Healy, Bridget and Jefferies, Sarah and Weatherall, Mark and Beasley, Richard},\n\tyear = {2013},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Comparative audit of oxygen use in the prehospital setting in acute COPD exacerbation over 5 years.\n \n \n \n\n\n \n Pilcher, J.; Cameron, L.; Braithwaite, I.; Bowles, D.; Swain, A.; Bailey, M.; Weatherall, M.; Beasley, R.; and Perrin, K.\n\n\n \n\n\n\n Emergency medicine journal : EMJ, 32. 2013.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pilcher_comparative_2013,\n\ttitle = {Comparative audit of oxygen use in the prehospital setting in acute {COPD} exacerbation over 5 years},\n\tvolume = {32},\n\tdoi = {10.1136/emermed-2013-203094},\n\tjournal = {Emergency medicine journal : EMJ},\n\tauthor = {Pilcher, Janine and Cameron, Laird and Braithwaite, Irene and Bowles, Darren and Swain, Andrew and Bailey, Mark and Weatherall, Mark and Beasley, Richard and Perrin, Kyle},\n\tyear = {2013},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2012\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n The risk of serious adverse outcomes associated with hypoxaemia and hyperoxaemia in acute exacerbations of COPD.\n \n \n \n\n\n \n Cameron, L.; Pilcher, J.; Weatherall, M.; Beasley, R.; and Perrin, K.\n\n\n \n\n\n\n Postgraduate medical journal, 88. 2012.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{cameron_risk_2012,\n\ttitle = {The risk of serious adverse outcomes associated with hypoxaemia and hyperoxaemia in acute exacerbations of {COPD}},\n\tvolume = {88},\n\tdoi = {10.1136/postgradmedj-2012-130809},\n\tjournal = {Postgraduate medical journal},\n\tauthor = {Cameron, Laird and Pilcher, Janine and Weatherall, Mark and Beasley, Richard and Perrin, Kyle},\n\tyear = {2012},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2011\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n The Effect of Supplemental Oxygen on Hypercapnia in Subjects With Obesity-Associated Hypoventilation A Randomized, Crossover, Clinical Study.\n \n \n \n\n\n \n Wijesinghe, M.; Williams, M.; Perrin, K.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Chest, 139: 1018–1024. 2011.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{wijesinghe_effect_2011,\n\ttitle = {The {Effect} of {Supplemental} {Oxygen} on {Hypercapnia} in {Subjects} {With} {Obesity}-{Associated} {Hypoventilation} {A} {Randomized}, {Crossover}, {Clinical} {Study}},\n\tvolume = {139},\n\tdoi = {10.1378/chest.10-1280},\n\tjournal = {Chest},\n\tauthor = {Wijesinghe, Meme and Williams, Mathew and Perrin, Kyle and Weatherall, Mark and Beasley, Richard},\n\tyear = {2011},\n\tpages = {1018--1024},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Towards individualised treatment in COPD.\n \n \n \n\n\n \n Fingleton, J.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Thorax, 66: 363–364. 2011.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{fingleton_towards_2011,\n\ttitle = {Towards individualised treatment in {COPD}},\n\tvolume = {66},\n\tdoi = {10.1136/thx.2010.155564},\n\tjournal = {Thorax},\n\tauthor = {Fingleton, James and Weatherall, Mark and Beasley, Richard},\n\tyear = {2011},\n\tpages = {363--364},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The value of the CRB65 score to predict mortality in exacerbations of COPD requiring hospital admission.\n \n \n \n\n\n \n Edwards, L.; Perrin, K.; Wijesinghe, M.; Weatherall, M.; Beasley, R.; and Travers, J.\n\n\n \n\n\n\n Respirology (Carlton, Vic.), 16: 625–629. 2011.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{edwards_value_2011,\n\ttitle = {The value of the {CRB65} score to predict mortality in exacerbations of {COPD} requiring hospital admission},\n\tvolume = {16},\n\tdoi = {10.1111/j.1440-1843.2011.01926.x},\n\tjournal = {Respirology (Carlton, Vic.)},\n\tauthor = {Edwards, Llifon and Perrin, Kyle and Wijesinghe, Meme and Weatherall, Mark and Beasley, Richard and Travers, Justin},\n\tyear = {2011},\n\tpages = {625--629},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n High-concentration oxygen therapy in COPD.\n \n \n \n\n\n \n Beasley, R.; Patel, M.; Perrin, K.; and Ronan O'Driscoll, B\n\n\n \n\n\n\n Lancet, 378: 969–970. 2011.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{beasley_high-concentration_2011,\n\ttitle = {High-concentration oxygen therapy in {COPD}},\n\tvolume = {378},\n\tdoi = {10.1016/S0140-6736(11)61431-1},\n\tjournal = {Lancet},\n\tauthor = {Beasley, Richard and Patel, Mitesh and Perrin, Kyle and Ronan O'Driscoll, B},\n\tyear = {2011},\n\tpages = {969--970},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);